KPV (Lysine-Proline-Valine)

KPV is a tripeptide representing the C-terminal fragment of alpha-melanocyte stimulating hormone (α-MSH). Despite lacking the melanogenic activity of full-length α-MSH or its N-terminal fragments, KPV retains potent anti-inflammatory properties. This makes it a valuable research tool for studying inflammation without the confounding effects of melanogenesis. The anti-inflammatory effects of α-MSH were initially attributed to melanocortin receptor activation, but KPV's activity (without significant MC receptor binding) suggests alternative mechanisms for the anti-inflammatory properties of melanocortin peptides.

KPV exerts anti-inflammatory effects through non-melanocortin pathways: **NF-κB Inhibition:** KPV inhibits the nuclear factor kappa-B (NF-κB) signaling pathway, a master regulator of inflammatory gene expression. This reduces production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. **Inflammasome Modulation:** Research indicates KPV may affect NLRP3 inflammasome activation, reducing IL-1β maturation and release. This pathway is important in various inflammatory conditions. **Direct Cellular Entry:** Unlike receptor-mediated signaling, KPV can enter cells directly due to its small size and amino acid composition. This may allow it to interact with intracellular signaling components directly. **JAK/STAT Pathway:** Some studies suggest KPV affects Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling, another major inflammatory pathway.